Washington
Ended · Cassidy Q3 2026 · filed Oct 20Lobbying Q3 $270K −6.9% QoQ
YoY −18.2% vs Q3 2025
Members 0 90 days
Buys / sells 0 / 0 0 trades
HCRHealth Issues
8 quarters Open in Washington ›
HIMS
Hims & Hers Health, Inc.$27.59 −0.12 (−0.43%)
Oct 26 4:00 PM ET · prev $27.71
Market cap
$6.8B
Mid cap
Consensus
Buy
41% Buy or better · 22 analysts
Median target
$31.00
+12% · range $23.00–42.00
Next earnings
Nov 9
in 13 days
1 year
−42.8%
from $48.23 · Oct 27
30 days
−4.1%
from $28.78
52-week range
$14.52–48.23
−43% from high · low Feb 27
Avg volume 20D
9.88M
shares / day
Short interest
🔒 Subscribers only
Insider net
−$4.0M
0 buyers · 5 sellers · since Aug 14
New fund stakes
1
Q2 2026 13F · 4 exits
Reddit crowd
60°
Warm · 6 mentions this week
SecBot read BEARISH 8 reports · 90 days
Balance 3 bearish · 0 bullish · 1 mixed · 4 neutral oldest → newest, height = score
Avg score ·High conf. 6/8 ·Next Earnings date, Nov 9, 2026
Price
Daily candles with volume. Pins mark insider trades, rating changes, 13F stakes, reports, catalysts and short-interest jumps.
No data for this timeframe.
- R Jun 2 Hims & Hers completed its acquisition of Eucalyptus, an Australian d…
- R Aug 10 Hims & Hers Health reported Q2 2026 revenue of $753.2M (+38% YoY), s…
- S Aug 17 to Aug 19 3 days of insider sells: $1.6M by 3 insiders, avg $27.91
- S Sep 2 1 insider sell $98.0K at $28.33
- S Sep 15 to Sep 22 4 days of insider sells: $2.0M by 4 insiders, avg $29.07
- S Sep 30 to Oct 1 2 days of insider sells: $160.4K by 2 insiders, avg $29.36
- E Sep 30 M&A: Robbins LLP Urges HIMS Stockholders to Contact the Firm fo…
- S Oct 14 1 insider sell $100.6K at $29.06
Signal stack
Where each data set points today.
- InsidersBEARISH
5 insiders sold $4.0M.
- InstitutionsMIXED
Q2 2026: 36 added (1 new), 39 trimmed or exited. Largest new: Baillie Gifford & $26.0M.
- AnalystsBULLISH
9 of 22 rate it Buy or better. Median target $31.00 (+12%).
- TrendDOWNTREND
5% below its 50-day average.
- SocialQUIET
Crowd 60° (warm) this week from 6 mentions: 3 bullish, 1 bearish. No setup call. Excludes 2 subscriber-only days.
Who's buying
13F· Q2 20261
new positions
4
exits
$26.0M
in new stakes
| Fund | Move | Value |
|---|---|---|
| GOLDMAN SACHS GROUP INC | DOUBLED | $179.4M |
| FMR LLC | DOUBLED | $149.9M |
| MARSHALL WACE, LLP | DOUBLED | $146.2M |
| UBS Group AG | TRIM | $92.3M |
| BANK OF AMERICA CORP /DE/ | TRIM | $80.2M |
| PRINCIPAL FINANCIAL GROUP INC | ADD | $57.8M |
| SCHRODER INVESTMENT MANAGEMENT GROUP | ADD | $37.7M |
| JANE STREET GROUP, LLC | DOUBLED | $34.7M |
Quarterly 13F filings are due 45 days after each quarter ends.
The Street
22 analysts 41% rate it Buy or better
12-month targets · 13 analysts
$27.59 $23.00 $31.00 $42.00
Price is inside the target range. Median implies +12%.Targets as of Oct 27, 2026.
Recent actions
| Date | Firm | Rating |
|---|---|---|
| Aug 24, 2026 | Truist Securities MAINTAIN | Hold |
| Aug 21, 2026 | Barclays MAINTAIN | Overweight |
| Aug 11, 2026 | Citigroup MAINTAIN | Neutral |
| Aug 11, 2026 | Deutsche Bank MAINTAIN | Hold |
| Aug 11, 2026 | B of A Securities MAINTAIN | Neutral |
| Aug 11, 2026 | TD Cowen MAINTAIN | Hold |
Insider ledger
Form 4$0
bought · 0 insiders
$4.0M
sold · 5 insiders
| Date | Insider | Type | Value |
|---|---|---|---|
| Oct 14, 2026 | Boughton Soleil Chief Legal Officer | SELL | $100.6K |
| Oct 1, 2026 | Okupe Oluyemi Chief Financial Officer | SELL | $59.4K |
| Sep 30, 2026 | Boughton Soleil Chief Legal Officer | SELL | $101.0K |
| Sep 22, 2026 | Okupe Oluyemi Chief Financial Officer | SELL | $876.8K |
| Sep 22, 2026 | Okupe Oluyemi Chief Financial Officer | EXERCISE | $70.1K |
| Sep 17, 2026 | Okupe Oluyemi Chief Financial Officer | SELL | $354.9K |
| Sep 16, 2026 | Boughton Soleil Chief Legal Officer | SELL | $173.7K |
| Sep 15, 2026 | Elshenawy Mohamed CTO | SELL | $225.8K |
Earnings setup
EstimatesNov 9
reports in 13 days
Revision history: 🔒 Fresh data, subscribers only
| Period | EPS est. | Range | 30D rev. | Revenue |
|---|---|---|---|---|
| Current Q | 🔒 Fresh data, subscribers only | |||
| Next Q | 🔒 Fresh data, subscribers only | |||
| Current FY | 🔒 Fresh data, subscribers only | |||
| Next FY | 🔒 Fresh data, subscribers only | |||
Reddit mentions per day, 14 days
Crowd this week 60° Warm 3 bullish · 1 bearish
Mentions, 7 days 6 0 in posts · 6 in comments
Recent posts
30 days of selling premium: $2,301 realized, RIOT alone was $1,134
1 upvotes · 2 comments
$HIMS
1 upvotes · 0 comments
Recent comments
Fresh comment, for subscribers
Fresh comment, for subscribers
the 0% CSPs part is honestly the bit i respect most here. sitting in cash when you want to be doing something is brutal, esp going into a week like this one. SOFI Tue, FOMC Wed, MSFT and GOOGL Wed, AMZN Thu, that is not a week i want to be selling fresh puts into anyway.
size small and assume assignment has been the whole lesson for me too. my boring version is just small, on stuff i already own. HIMS $30 covered call expired worthless Fri, kept the shares and the $120, no roll, will do a month
boring is underrated honestly, cash at 69 percent and not forcing anything is half the strategy with this stuff. i manage the other way though, default for me is hold to expiry instead of taking the quick win. my HIMS $30 covered call expired worthless on friday, kept the shares and the $120 premium, no roll, just selling the monthly again monday. october is sitting at $1,617 in premium for me, best month so far. and it was not from doing more, if anything the opposite.
Short side
FINRA· Oct 15, 2026🔒 Subscribers only
shares short
Recent activity
The latest filings, insider trades, analyst actions, press and options flow — newest first.
Oct 26, 2026 Other
🔒 Fresh data, subscribers only
Oct 14, 2026 Insider
Oct 7, 2026 SEC Boughton Soleil sold 3,461 shares
Chief Legal Officer @ $29.06 ($100.6K)
Hims & Hers appointed Jonathan M. Franklin as chief accounting officer and principal accounting officer, effective…
8-K — Impact 3/10
Oct 1, 2026 Insider
Okupe Oluyemi sold 2,000 shares
Chief Financial Officer @ $29.70 ($59.4K)
Sep 30, 2026 Insider
Sep 23, 2026 SEC Boughton Soleil sold 3,461 shares
Chief Legal Officer @ $29.17 ($101.0K)
Four C-suite insiders at Hims & Hers Health sold a combined $1.67M in open-market sales over a one-week window…
CLUSTER — Impact 5/10
Four senior executives at Hims & Hers Health, including the CFO, COO, CTO, and Chief Legal Officer, sold a total of…
CLUSTER — Impact 4/10
Jul 29, 2026 Event
FTC and States Act Against Hims & Hers for Deceptive and Unlawful Privacy Practices
Complaint alleges telehealth provider shared consumers’ sensitive health information with third-part
Catalysts
Scheduled dates and disclosed events: earnings, FDA and trial readouts, halts, press releases. Colored dot = impact.
Upcoming
Recent
Oct 26, 2026
Press release
🔒 Fresh data, subscribers only
Oct 25, 2026
Press release
INVESTOR DEADLINE: Hims & Hers Health, Inc. (HIMS) Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit Before November 2, 2026 Deadline
SAN DIEGO, Oct. 25, 2026 /PRNewswire/ -- Robbins Geller Rudman & Dowd LLP announces that purchasers or acquirers of Hims & Hers Health, Inc. (NYSE…
Oct 23, 2026
Press release
HIMS 10-DAY DEADLINE ALERT: Hims & Hers Health Facing Securities Class Action Lawsuit, Investors with Losses Encouraged to Contact Hagens Berman
SAN FRANCISCO, Oct. 23, 2026 /PRNewswire/ -- Hims & Hers Health, Inc. (NYSE: HIMS) and certain company executives now face a securities class action…
Oct 21, 2026
Press release
INVESTOR NOTICE: Hims & Hers Health, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit Before November 2, 2026 Deadline - HIMS
SAN DIEGO, Oct. 21, 2026 /PRNewswire/ -- The law firm of Robbins Geller Rudman & Dowd LLP announces that purchasers or acquirers of Hims & Hers…
Oct 21, 2026
Press release
HIMS 12-DAY DEADLINE ALERT: Hims & Hers Health Faces Securities Fraud Class Action, Investors with Losses Encouraged to Contact Hagens Berman
SAN FRANCISCO, Oct. 21, 2026 /PRNewswire/ -- Hims & Hers Health, Inc. (NYSE: HIMS) and certain company executives now face a securities class action…
SecBot reports
18 filings · 1 bullish · 4 bearish · 2 mixed · 11 neutral- NEUTRAL 8-KOct 7, 2026
Hims & Hers appointed Jonathan M. Franklin as chief accounting officer and principal accounting…
Monitor for any further board or C-suite changes that may signal the activist's influence, particularly ahead of the next earnings report. The orderly transition of the accounting officer role is a…
- BEARISH CLUSTERSep 23, 2026
Four C-suite insiders at Hims & Hers Health sold a combined $1.67M in open-market sales over a…
The breadth of C-suite selling — CFO, COO, CTO, CLO all selling within 8 days with no plan protection — is a rare and strong bearish signal. Monitor for an upcoming earnings pre-announcement or…
- BEARISH CLUSTERSep 18, 2026
Four senior executives at Hims & Hers Health, including the CFO, COO, CTO, and Chief Legal…
Watch for any subsequent 8-K filings (e.g., earnings pre-announcement, guidance change, or material agreement) in the next 2-4 weeks that could explain the cluster. The absence of a 10b5-1 plan…
- BEARISH CLUSTERSep 17, 2026
Two senior executives at Hims & Hers Health (COO and CTO) sold a combined $624K in open-market…
The simultaneous open-market sales by both the COO and CTO on the same day, without a disclosed 10b5-1 plan, is a bearish signal. Monitor for any upcoming earnings pre-announcement, regulatory news…
All HIMS filing & press-release reports (18)
- 8-K reportOct 7, 2026
- CLUSTER reportSep 23, 2026
- CLUSTER reportSep 18, 2026
- CLUSTER reportSep 17, 2026
- CLUSTER reportAug 20, 2026
- CLUSTER reportAug 20, 2026
- CLUSTER reportAug 18, 2026
- 8-K reportAug 10, 2026
- 8-K reportJul 1, 2026
- CLUSTER reportJun 17, 2026
- INST-CLUSTER reportJun 11, 2026
- 8-K reportJun 2, 2026
- 8-K reportMay 21, 2026
- 8-K reportMay 19, 2026
- 8-K reportMay 11, 2026
- DEFA14A reportApr 28, 2026
- CLUSTER reportMar 17, 2026
- CLUSTER reportMar 17, 2026